News
AXSM
120.36
-6.82%
-8.81
Axsome Therapeutics announces FOCUS Phase 3 trial achieved primary endpoint
TipRanks · 6h ago
Axsome Therapeutics’ Promising Phase III FOCUS Trial Results Boost Buy Rating
TipRanks · 10h ago
Axsome Therapeutics Lower Dose Of Attention Deficient Disorder Candidate Hits Primary Goal
Benzinga · 10h ago
AXSOME THERAPEUTICS SHARES FALL 1% AFTER CO REPORTS LATE-STAGE DATA FOR ADHD DRUG
Reuters · 12h ago
Positive Phase 3 Trial Results for Axsome Therapeutics’ Solriamfetol Drive Buy Rating Amid Market Uncertainties
TipRanks · 13h ago
Axsome succeeds in late-stage trial for ADHD therapy
Seeking Alpha · 14h ago
AXSOME THERAPEUTICS INC: STATISTICALLY SIGNIFICANT REDUCTION IN OVERALL ADHD DISEASE SEVERITY AS MEASURED BY CGI-S SCORE COMPARED TO PLACEBO
Reuters · 14h ago
AXSOME THERAPEUTICS : STATISTICALLY SIGNIFICANT IMPROVEMENT IN ADHD SYMPTOMS AS MEASURED BY AISRS TOTAL SCORE COMPARED TO PLACEBO
Reuters · 14h ago
AXSOME THERAPEUTICS ANNOUNCES FOCUS PHASE 3 TRIAL OF SOLRIAMFETOL IN ADULTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) ACHIEVES PRIMARY ENDPOINT
Reuters · 14h ago
Axsome Therapeutics' Says FOCUS Phase 3 Trial Of Solriamfetol In The Treatment Of Attention Deficit Hyperactivity Disorder Achieved Its Primary And Key Secondary Endpoints Demonstrating Statistically Significant Improvements In Symptoms And Disease Severity Compared To Placebo
Benzinga · 14h ago
Strong Growth and Positive Outlook for Axsome Therapeutics’ Auvelity Drives Buy Rating
TipRanks · 1d ago
Weekly Report: what happened at AXSM last week (0317-0321)?
Weekly Report · 1d ago
Strong Market Performance and Growth Potential of Auvelity Drives Positive Outlook for Axsome Therapeutics
TipRanks · 2d ago
Axsome: The Alzheimer's Agitation Program For AXS-05
Seeking Alpha · 4d ago
Lazard US Equity Concentrated Portfolio Q4 2024 Commentary
Seeking Alpha · 5d ago
HRMY Down 10.8% in Six Months: How Should You Play the Stock?
Barchart · 6d ago
Weekly Report: what happened at AXSM last week (0310-0314)?
Weekly Report · 03/17 10:53
Will Auvelity & Other Drugs Aid AXSM's Growth Amid Stiff Competition?
NASDAQ · 03/14 14:55
We Did The Math FNX Can Go To $137
NASDAQ · 03/13 11:50
Weekly Report: what happened at AXSM last week (0303-0307)?
Weekly Report · 03/10 10:55
More
Webull provides a variety of real-time AXSM stock news. You can receive the latest news about Axsome Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About AXSM
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.